Abstract
PDB52 - Cost Effectiveness of Empagliflozin in Patients with T2DM and High CV Risk in Canada
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have